MedTrace Logo

Direct Acting Anti-Viral's In Chronic HCV Patients

NCT04664894 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 511

Last updated 2020-12-11

No results posted yet for this study

Summary

The objective of the study is to determine the safety of DAA's among chronic HCV patients. The outcomes of the study are; To determine the frequency of adverse events while receiving DAAs with or without RBV and/or Pegylated Interferon To calculate the percentage of patients with severity of medical event as per Karch and Lasagna classification To determine the percentage of patient having serious adverse event as per ICH Classification

Conditions

  • Safety Issues

Interventions

DRUG

Sofosbuvir

the occurrence of AEs (AE) and their severity among chronic HCV patients has assessed in patinets receiving different combinations of DAAs in Pakistani Population

Sponsors & Collaborators

  • Getz Pharma

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-15
Primary Completion
2019-05-30
Completion
2019-05-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04664894 on ClinicalTrials.gov